The plasma peptides of ovarian cancer
Authors:
- Jaimie DufresneJDJaimie Dufresne
- Pete BowdenPBPete Bowden
- Thanusi ThavarajahTTThanusi Thavarajah
- Angelique Florentinus-MefailoskiAFAngelique Florentinus-Mefailoski
- Zhuo Zhen ChenZCZhuo Zhen Chen
- Monika TucholskaMTMonika Tucholska
- Tenzin NorzinTNTenzin Norzin
- Margaret Truc HoMHMargaret Truc Ho
- Morla PhanMPMorla Phan
- Nargiz MohamedNMNargiz Mohamed
- Amir RavandiARAmir Ravandi
- Eric StantonESEric Stanton
Open Access
- 21 December 2018
- journal article
- research article
- Published by Springer Nature in Clinical Proteomics
- Vol. 15 (1) , 1-19
Abstract
It may be possible to discover new diagnostic or therapeutic peptides or proteins from blood plasma by using liquid chromatography and tandem mass spectrometry to identify, quantify and compare the peptides cleaved ex vivo from different clinical populations. The endogenous tryptic peptides of ovarian cancer plasma were compared to breast cancer and female cancer normal controls, other diseases with their matched or normal controls, plus ice cold plasma to control for pre-analytical variation. The endogenous tryptic peptides or tryptic phospho peptides (i.e. without exogenous digestion) were analyzed from 200 μl of EDTA plasma. The plasma peptides were extracted by a step gradient of organic/water with differential centrifugation, dried, and collected over C18 for analytical HPLC nano electrospray ionization and tandem mass spectrometry (LC–ESI–MS/MS) with a linear quadrupole ion trap. The endogenous peptides of ovarian cancer were compared to multiple disease and normal samples from different institutions alongside ice cold controls. Peptides were randomly and independently sampled by LC–ESI–MS/MS. Precursor ions from peptides > E4 counts were identified by the SEQUEST and X!TANDEM algorithms, filtered in SQL Server, before testing of frequency counts by Chi Square (χ2), for analysis with the STRING algorithm, and comparison of precursor intensity by ANOVA in the R statistical system with the Tukey-Kramer Honestly Significant Difference (HSD) test. Peptides and/or phosphopeptides of common plasma proteins such as HPR, HP, HPX, and SERPINA1 showed increased observation frequency and/or precursor intensity in ovarian cancer. Many cellular proteins showed large changes in frequency by Chi Square (χ2 > 60, p < 0.0001) in the ovarian cancer samples such as ZNF91, ZNF254, F13A1, LOC102723511, ZNF253, QSER1, P4HA1, GPC6, LMNB2, PYGB, NBR1, CCNI2, LOC101930455, TRPM5, IGSF1, ITGB1, CHD6, SIRT1, NEFM, SKOR2, SUPT20HL1, PLCE1, CCDC148, CPSF3, MORN3, NMI, XTP11, LOC101927572, SMC5, SEMA6B, LOXL3, SEZ6L2, and DHCR24. The protein gene symbols with large Chi Square values were significantly enriched in proteins that showed a complex set of previously established functional and structural relationships by STRING analysis. Analysis of the frequently observed proteins by ANOVA confirmed increases in mean precursor intensity in ZFN91, TRPM5, SIRT1, CHD6, RIMS1, LOC101930455 (XP_005275896), CCDC37 and GIMAP4 between ovarian cancer versus normal female and other diseases or controls by the Tukey–Kramer HSD test. Here we show that separation of endogenous peptides with a step gradient of organic/water and differential centrifugation followed by random and independent sampling by LC–ESI–MS/MS with analysis of peptide frequency and intensity by SQL Server and R revealed significant difference in the ex vivo cleavage of peptides between ovarian cancer and other clinical treatments. There was striking agreement between the proteins discovered from cancer plasma versus previous biomarkers discovered in tumors by genetic or biochemical methods. The results indicate that variation in plasma proteins from ovarian cancer may be directly discovered by LC–ESI–MS/MS that will be a powerful tool for clinical research.Keywords
All Related Versions
Funding Information
- Natural Science and Engineering Research Council of Canada
This publication has 91 references indexed in Scilit:
- Quantitative Statistical Analysis of Standard and Human Blood Proteins from Liquid Chromatography, Electrospray Ionization, and Tandem Mass SpectrometryJournal of Proteome Research, 2012
- Post-translational modifications of the extracellular matrix are key events in cancer progression: Opportunities for biochemical marker developmentBiomarkers, 2011
- Mass spectrometry of peptides and proteins from human bloodMass Spectrometry Reviews, 2010
- Array‐CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genesGenes, Chromosomes and Cancer, 2010
- An insight into high-resolution mass-spectrometry dataBiostatistics, 2009
- Proteomic profiling of human plasma exosomes identifies PPARγ as an exosome-associated proteinBiochemical and Biophysical Research Communications, 2009
- UC/MALDI-MS analysis of HDL; evidence for density-dependent post-translational modificationsInternational Journal of Mass Spectrometry, 2007
- Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post‐translational modificationsProteomics, 2007
- Characterization of SEZ6L2 cell‐surface protein as a novel prognostic marker for lung cancerCancer Science, 2006
- The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two‐dimensional electrophoresis gels and identification of 325 distinct proteinsProteomics, 2003